123 related articles for article (PubMed ID: 33544314)
1. Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma.
Huang SC; Liao SH; Su TH; Jeng YM; Kao JH
Hepatol Int; 2021 Apr; 15(2):472-481. PubMed ID: 33544314
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Patients with Scirrhous Hepatocellular Carcinoma: Insights from the National Cancer Database.
Farooq A; Merath K; Paredes AZ; Wu L; Tsilimigras DI; Hyer JM; Sahara K; Mehta R; Beal EW; Pawlik TM
J Gastrointest Surg; 2020 May; 24(5):1049-1060. PubMed ID: 31243715
[TBL] [Abstract][Full Text] [Related]
3. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma.
Yang SY; Wang CC; Chen KD; Liu YW; Lin CC; Chuang CH; Tsai YC; Yao CC; Yen YH; Hsiao CC; Hu TH; Tsai MC
BMC Cancer; 2021 Jan; 21(1):70. PubMed ID: 33446127
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
5. Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis.
Hsu CY; Liu PH; Lee YH; Hsia CY; Huang YH; Chiou YY; Tsai YJ; Nagaria TS; Huo TI
Ann Surg Oncol; 2015 Apr; 22(4):1324-31. PubMed ID: 25326394
[TBL] [Abstract][Full Text] [Related]
6. Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma.
Liao SH; Su TH; Jeng YM; Liang PC; Chen DS; Chen CH; Kao JH
Hepatology; 2019 Jan; 69(1):209-221. PubMed ID: 30014620
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
8. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation.
Chen PH; Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Huo TI; Huang YH; Wu WC; Chao Y; Lin HC; Wu JC
Ann Hepatol; 2013; 12(2):263-73. PubMed ID: 23396738
[TBL] [Abstract][Full Text] [Related]
10. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
[TBL] [Abstract][Full Text] [Related]
11. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study.
Espinosa W; Liu YW; Wang CC; Lin CC; Wang JH; Lu SN; Hung CH
J Formos Med Assoc; 2018 Mar; 117(3):197-203. PubMed ID: 28411877
[TBL] [Abstract][Full Text] [Related]
12. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis.
Shim JH; Yoon DL; Han S; Lee YJ; Lee SG; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Ann Surg Oncol; 2012 Nov; 19(12):3687-96. PubMed ID: 22644512
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification.
Lee M; Chang Y; Oh S; Cho YY; Jung DE; Kim HH; Nam JY; Cho H; Cho EJ; Lee JH; Yu SJ; Yi NJ; Lee KW; Lee DH; Lee JM; Yoon JH; Suh KS; Kim YJ
Gut Liver; 2018 Sep; 12(5):571-582. PubMed ID: 29730905
[TBL] [Abstract][Full Text] [Related]
15. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis.
Yang T; Lu JH; Lau WY; Zhang TY; Zhang H; Shen YN; Alshebeeb K; Wu MC; Schwartz M; Shen F
J Hepatol; 2016 Mar; 64(3):583-93. PubMed ID: 26596543
[TBL] [Abstract][Full Text] [Related]
16. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model.
Hsu CY; Lee YH; Liu PH; Hsia CY; Huang YH; Lin HC; Chiou YY; Lee FY; Huo TI
PLoS One; 2014; 9(2):e89373. PubMed ID: 24586728
[TBL] [Abstract][Full Text] [Related]
17. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection.
Young SH; Chau GY; Lee IC; Yeh YC; Chao Y; Huo TI; Su CW; Lin HC; Hou MC; Lee MH; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):218-229. PubMed ID: 31104872
[TBL] [Abstract][Full Text] [Related]
18. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
19. The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection.
Wang G; Zhang W; Tan Y; Jiang L; Yang J; Yang J; Yan L
Int J Surg; 2019 Dec; 72():1-6. PubMed ID: 31610283
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.
Kim HD; Lim YS; Han S; An J; Kim GA; Kim SY; Lee SJ; Won HJ; Byun JH
Gastroenterology; 2015 Jun; 148(7):1371-82. PubMed ID: 25733098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
